The ONE and ONLY ready-to-use* liquid zonisamide
*Shake well before administering.
Medication
Transformed
Of the 20+ FDA-approved oral formulations of zonisamide, ZONISADE® is the ONLY alternative formulation to solid doses.1
Azurity Pharmaceuticals is thrilled to support the work of the epilepsy community and to have the opportunity to help patients and their families. Select a support or advocacy organization and Azurity will make a $25 donation to its cause. Thank you for joining us with your support!
Select organization
Zonisamide History
Zonisamide was first approved in the United States in 2000 as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy.2
Quality & Reliability
Azurity medications comply with Current Good Manufacturing Practice (CGMP) regulations to help ensure consistency from pharmacy to pharmacy.3
Tailored Approach
Ready-to-use* oral liquids provide flexible dosing to meet a patient’s individual needs.
*Shake well before administering.
Product labeling, packaging, and imagery are for representation purposes only.
ZONISADE® is indicated for adjunctive therapy for the treatment of partial-onset seizures in adults and pediatric patients 16 years of age and older.
Oral liquids may help overcome certain barriers to treatment success
*ZONISADE® does not have head-to-head data on adherence.4
†A calibrated measuring device is recommended to measure and deliver the prescribed dose accurately. A household teaspoon or tablespoon is not an adequate measuring device. Once opened, unused portion should be discarded after 30 days.
Finally, an alternative to zonisamide capsules
ZONISADE®, the ONE and ONLY FDA-approved ready-to-use* oral liquid zonisamide.
Adjunctive therapy for the management of epilepsy to support those who need additional medication†
Long half-life enables once-daily dosing2‡
- Patients who miss a dose should resume dosing at their next regularly scheduled dose—no makeup dose needed
Clinical trials have shown zonisamide to be well tolerated with a good safety profile, which is supported by an excess of 2 million patient-years of clinical exposure4
American Epilepsy Society Guidelines include zonisamide for use in treatment-resistant epilepsy based on Level A, B Recommendations5
- Level A recommendations are established as effective to reduce seizure frequency
- Level B recommendations should be considered to reduce seizure frequency
The ready-to-use* oral liquid formulation of ZONISADE® eliminates the need for crushing and compounding
- Zonisamide powder can have a bitter taste6
- Zonisamide is listed by the National Institute for Occupational Safety and Health (NIOSH) as a hazardous drug that may require safe handling guidance7
*Shake well before administering.
†Cannot be used together with topiramate as adjunctive therapy.
‡After a single-dose administration, renal clearance of zonisamide is approximately 3.5 mL/min. The clearance of an oral dose of zonisamide from red blood cells is 2 mL/min. The elimination half-life of zonisamide in plasma is approximately 63 hours.
Did you know?
~34%
of FDA-sampled compounded products failed one or more standard quality tests performed, including potency testing.8
The ready-to-use* oral liquid formulation of ZONISADE® eliminates the need for compounding
Azurity medications comply with the FDA’s Current Good Manufacturing Practice (CGMP) guidelines, which regulate quality and purity of drugs.3
*Shake well before administering.
Strategies to improve adherence include pleasant-tasting medications and liquid formulations†
†ZONISADE® does not have head-to-head data on adherence.4
Did you know?
Disliking taste and difficulty swallowing were considered
barriers to clinical outcomes
for adolescent epilepsy patients.9
Did you know?
Survey results of 1051 adult general-practice patients with trouble swallowing revealed that 59% modified their drugs (splitting, crushing, opening capsules) to facilitate administration, and almost half were unaware it could affect safety and/or efficacy.10
The ready-to-use* oral liquid formulation of ZONISADE® eliminates the need for compounding7
*Shake well before administering.
The strawberry flavor of ZONISADE® may help enhance palatability
Did you know?
Zonisamide powder can have a bitter taste.6
Zonisamide is listed by the National Institute for Occupational Safety and Health (NIOSH) as a hazardous drug that may require safe handling guidance.7
Did you know?
Patients who miss a dose of ZONISADE® should resume dosing at their next regularly scheduled dose—no makeup dose needed.2
The long half-life of ZONISADE® enables once-daily dosing2
ZONISADE®: A tailored approach to dosing
Storage and administration
ZONISADE® can be stored at room temperature and should be protected from light.
ZONISADE® is a liquid suspension and should be shaken well before every administration. To administer directly into the mouth, it is important that ZONISADE® be measured with an accurate measuring device. A household teaspoon is not an accurate measuring device. Once opened, unused portions should be discarded after 30 days.
ZONISADE® should be administered once or twice daily with or without food. Its strawberry flavor may help enhance palatability.
ZONISADE® Conversion Calculator: Calculate mg to mL with precision
The recommended initial dose of ZONISADE® is 100 mg daily. The dosage may be increased by 100 mg daily every 2 weeks to 400 mg daily based on clinical response and tolerability. Patients who are tolerating ZONISADE® at 400 mg daily and require further reduction of seizures may be increased up to a maximum dosage of 600 mg daily. However, evidence from controlled trials shows no suggestion of increasing response above 400 mg/day.
ZONISADE® has a longer half-life of 105 hours, which allows for a once-daily dosing regimen and results in steady therapeutic drug levels. This means that if a patient misses a dose, they can resume dosing at the regular schedule without a makeup dose.2
| Dosing for Patients Aged 16 Years and Older* | ||
|---|---|---|
| Initial dose | 100 mg daily | |
| Beyond 2 weeks | May be increased by 100 mg/day every 2 weeks to 400 mg/day†,‡ | |
- ZONISADE® may be administered once or twice daily with or without food
- Safety and efficacy in pediatric patients below 16 years of age have not been established
*Measure with an accurate measuring device. A household teaspoon is not an accurate measuring device.
†Based on clinical response and tolerability.
‡Patients who are tolerating 400 mg/day and require further reduction of seizures may be increased up to a maximum dosage of 600 mg/day.
However, evidence from controlled trials shows no suggestion of increasing response above 400 mg/day.
